[Methotrexate in conjunction with meloxicam for treating ankylosing spondylitis: a clinical observation of the efficacy and safety].
2003; National Institutes of Health; Volume: 23; Issue: 5 Linguagem: Inglês
Autores
Rui-long Xie, Xiao-hao Li, Xian-tong Kang,
Tópico(s)Peripheral Neuropathies and Disorders
ResumoTo evaluate the efficacy and safety of combined use of methotrexate and meloxicam for treating of ankylosing spondylitis (AS), and to determine the optimal dosage of methotrexate.Thirty-two patients with AS were divided into group A (n=14) to receive oral methotrexate at the dose of 12.3+/-3.6 mg once a week and group B (n=18) at the dose of 21.3+/-3.2 mg once a week. Each of the patients in both groups also took oral meloxicam (7.5 mg) for 3 months.After treatment, the clinical indexes and inflammatory parameters of the patients significantly improved in both groups, with a total efficacy of 78.6% in group A and 88.9% in group B.The combination of methotrexate with meloxicam may achieve satisfactory results in AS treatment, which is not positively related to methotrexate dosage. In short-term usage, meloxicam does not increase the toxicity of methotrexate.
Referência(s)